Results 181 to 190 of about 2,756,439 (291)

Bivalent RSVpreF Subunit Vaccine Safety and Immunogenicity in Seropositive 2-<18 Year Olds. [PDF]

Vaccines (Basel)
Glanternik J, Paulsen GC, Senders S, Smith M, Shittu E, Pahud BA, Pereira L, Chen L, Maddalena Lino M, Kalinina EV, Baranova D, Kalina WV, Needle E, Murillo M, Leech JM, Cooper D, Swanson KA, Anderson AS, Gurtman A, Munjal I.   +19 more
europepmc   +1 more source

Immunoinformatics‐Based Design of a Multi‐Epitope Vaccine Targeting a Conserved Copper–Associated Protein in Neisseria gonorrhoeae

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Neisseria gonorrhoeae poses an urgent public health challenge due to rapidly increasing antimicrobial resistance and the absence of an effective vaccine. Targeting conserved bacterial pathways involved in essential physiological processes may provide new opportunities for vaccine antigen discovery.
Sinethemba H. Yakobi, Uchechukwu U. Nwodo   +1 more
wiley   +1 more source

Harmonizing Case Validation for Vaccine Safety in Real-World Data: The VAC4EU Experience. [PDF]

Clin Epidemiol
Dehghan Tarazjani A, Weibel D, Aurelius T, Zwiers LC, Van den Berg JM, Pérez-Breva L, Gimeno-Miguel A, Stona L, Solórzano M, Desalegn AA, Poblador-Plou B, Lysen TS, Wheler J, Zidan M, Carreras JJ, Villalobos F, Ehrenstein V, Morton K, Rebordosa C, Ahmadizar F, Fortuny J, Arana A, Sturkenboom M.   +22 more
europepmc   +1 more source

Targeting Amastigote and Trypomastigote Phases: Multi‐Epitope Vaccine Strategy Against Trypanosoma cruzi

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Effective vaccines against Trypanosoma cruzi, the causative agent of Chagas disease, are urgently needed. Here, we report the design and in silico validation of a novel multiepitope vaccine construct targeting the key surface proteins ASP‐2 and gp82. Using a comprehensive immunoinformatics pipeline, we identified and selected 38 potent T‐cell (
Maria Karolaynne da Silva, Caio Patrício de Souza Sena, Davi Serradella Vieira, Magdi E. A. Zaki, Leow Chiuan Yee, Shahina Akter, Umberto Laino Fulco, Jonas Ivan Nobre Oliveira, João Firmino Rodrigues‐Neto   +8 more
wiley   +1 more source

Pregnant Women and Vaccine Safety in Uganda: Knowledge, Barriers, and Opportunities for Engagement. [PDF]

Vaccines (Basel)
Nambasa VP, Komuhendo R, Serwanga A, Kajungu D, Koch BCP, Kampmann B, Le Doare K, Ssali A.   +7 more
europepmc   +1 more source

Current evidence and insights on single vs. double dose of basiliximab in adult solid organ transplant recipients: A systematic review

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this systematic review was to assess all available clinical data regarding the use of a single dose of basiliximab in solid organ transplantation compared to the standard double dosage, with particular interest in efficacy, safety and cost‐savings.
Alessio Provenzani, Braidon A. Lape, Anneliese M. Harp, Victoria Weisbrod, Lavinia Piazza   +4 more
wiley   +1 more source

Active Surveillance for COVID-19 Vaccine Safety Using Sequential Analysis in Korea: Population-Based Retrospective Observational Study. [PDF]

JMIR Public Health Surveill
Jeong NY, Cho H, Won H, Park S, Lee J, Park H, Choi NK.   +6 more
europepmc   +1 more source

Efficacy and safety of vaccines

Veterinary Quarterly, 1994
openaire   +2 more sources

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Vaccine Safety

, 2017
C. John Clements, Glenda L. Lawrence, Kristine K. Macartney   +2 more
openaire   +2 more sources